FIELD: bioengineering.
SUBSTANCE: claimed invention discloses the immunoconjugate for effector fragment delivery to influence cells activity. The said immunoconjugate comprises one single chain effector fragment and two antigen-binding fragments that represent a Fab molecule. Besides, this invention discloses the molecules of nucleic acids, encoding immunoconjugates, vectors and host cells containing the nucleic acid molecules, production of the said immunoconjugates described hereby and application thereof for disease treatment.
EFFECT: perfected properties.
133 cl, 53 dwg, 23 tbl, 28 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION COMPRISING TWO ANTIBODIES ENGINEERED TO HAVE REDUCED AND INCREASED EFFECTOR FUNCTION | 2013 |
|
RU2650788C2 |
| COMBINED THERAPY BASED ON TUMOUR-TARGETED IMMUNOCYTOKINES CONTAINING VARIANT IL-2, AND ANTIBODIES TO HUMAN PD-L1 | 2015 |
|
RU2710354C2 |
| NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH CAPABILITY OF SPECIFICALLY BINDING TO CD40 AND FAP | 2018 |
|
RU2766234C2 |
| BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE | 2012 |
|
RU2605390C2 |
| SINGLE LINKER ANTIBODIES FabFv AND METHODS FOR PRODUCING THEREOF | 2013 |
|
RU2714159C2 |
| BIOSPECIFIC ANTIGEN-BINDING MOLECULES | 2012 |
|
RU2650775C2 |
| ANTIBODIES TO CD70 | 2012 |
|
RU2604196C2 |
| ANTIBODY-BASED PROTEINS WITH CYTOKINE GRAFTS AND METHODS OF THEIR USE IN CANCER TREATMENT | 2018 |
|
RU2815389C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| ANTIBODIES AGAINST A2 TENASTIN-C AND METHODS FOR USE THEREOF | 2011 |
|
RU2584597C2 |
